One drug could cure rectal cancer, spare patients from surgery
NCT ID NCT05723562
Summary
This study is testing whether a single immunotherapy drug, dostarlimab, can effectively treat a specific type of rectal cancer without needing chemotherapy, radiation, or surgery. It involves 154 adults with untreated, locally advanced rectal cancer that has a specific genetic marker (dMMR/MSI-H). The main goal is to see if the drug alone can lead to a lasting complete response, allowing patients to keep their rectum and avoid more invasive treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS, RECTAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Albuquerque, New Mexico, 87131, United States
-
GSK Investigational Site
New York, New York, 10022, United States
-
GSK Investigational Site
Pittsburgh, Pennsylvania, 15232, United States
-
GSK Investigational Site
Nashville, Tennessee, 37203, United States
-
GSK Investigational Site
Dallas, Texas, 75390, United States
-
GSK Investigational Site
Richmond, Virginia, 23298, United States
-
GSK Investigational Site
Ottawa, Ontario, K1H 8L6, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 2M9, Canada
-
GSK Investigational Site
Montreal, Quebec, H2X 0C1, Canada
-
GSK Investigational Site
Sherbrooke, Quebec, J1H 5N4, Canada
-
GSK Investigational Site
Besançon, 25030, France
-
GSK Investigational Site
Marseille, 13273, France
-
GSK Investigational Site
Paris, 75012, France
-
GSK Investigational Site
Pessac, 33604, France
-
GSK Investigational Site
Rennes, 35000, France
-
GSK Investigational Site
Berlin, 13353, Germany
-
GSK Investigational Site
Dresden, 01307, Germany
-
GSK Investigational Site
Düsseldorf, 40225, Germany
-
GSK Investigational Site
Frankfurt, 60488, Germany
-
GSK Investigational Site
München, 81377, Germany
-
GSK Investigational Site
Milan, 20133, Italy
-
GSK Investigational Site
Padua, 35128, Italy
-
GSK Investigational Site
Roma, 00168, Italy
-
GSK Investigational Site
Chiba, 277-8577, Japan
-
GSK Investigational Site
Kanagawa, 232-0024, Japan
-
GSK Investigational Site
Osaka, 540-0006, Japan
-
GSK Investigational Site
Osaka, 565-0871, Japan
-
GSK Investigational Site
Utrecht, 3584 CX, Netherlands
-
GSK Investigational Site
Seoul, 05505, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Seoul, 120-752, South Korea
-
GSK Investigational Site
Seoul, 135-710, South Korea
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Granada, 18014, Spain
-
GSK Investigational Site
Madrid, 28007, Spain
-
GSK Investigational Site
Madrid, 28041, Spain
-
GSK Investigational Site
Santander, 39008, Spain
-
GSK Investigational Site
Valencia, 46010, Spain
-
GSK Investigational Site
Leeds West Yorkshire, LS9 7TF, United Kingdom
-
GSK Investigational Site
London, EC1A 7BE, United Kingdom
-
GSK Investigational Site
Sutton, SM2 5PT, United Kingdom
-
GSK Investigational Site
Los Angeles, California, 90027, United States
Conditions
Explore the condition pages connected to this study.